All In Biotech

Drug Trial Radar · NCT07790523

Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years

A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 410,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

410,000

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

May 31, 2028

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Tor Biering-SørensenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ModernaTX, Inc.
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this pragmatic randomized trials is to evaluate the comparative vaccine effectiveness (cVE) of mCombriax® (mRNA-1083) versus same day co-administration of the active comparators (i.e., high-dose influenza vaccine/Efluelda® and mRNA-1273/Spikevax®) among adults aged 65 years and older.

Conditions

  • COVID-19
  • Influenza

Interventions

  • mCombriax® (mRNA-1083)Biological

    An authorized mRNA-based multicomponent vaccine encoding antigens targeting both seasonal influenza and SARS-CoV-2 viruses.

  • Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)Biological

    Same-day co-administration of an authorized high-dose trivalent influenza vaccine (TIV-HD; Efluelda®) and an authorized COVID-19 mRNA vaccine (Spikevax®, mRNA-1273)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Medically attended influenza and/or COVID-19Time frame: From Day 14 after vaccination through the end of follow-up, up to 8 months after vaccination
  2. Influenza and/or COVID-19 hospitalizationTime frame: From Day 14 after vaccination through the end of follow-up, up to 8 months after vaccination

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

    Hellerup, Denmark

  • Danske Lægers Vaccinations Service

    Søborg, Denmark

  • General Public Health Directorate of Galician Health Service

    Santiago de Compostela, A Coruña, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.